NCT03964233: A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 and 754111

NCT03964233
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase (not the expansion phase)
Exclusions: Patients with active unstable or untreated brain metastases – see trial for details; Patients with prior treatment of BI 907828 or any other MDM2-p53 or MDMX (MDM4)-p53 antagonist, or anti-LAG-3 antibody
https://ClinicalTrials.gov/show/NCT03964233

Comments are closed.

Up ↑